{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:38Z","timestamp":1786993718339,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000950","name":"Cancer Council SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"German Academic Exchange Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.leukres.2024.107469","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:56:23Z","timestamp":1709812583000},"page":"107469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines"],"prefix":"10.1016","volume":"139","author":[{"given":"Mara N.","family":"Zeissig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan R.","family":"Hewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof M.","family":"Mrozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Wallington-Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Vandyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.W.","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2024.107469_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.leukres.2024.107469_bib4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.clml.2021.01.016","article-title":"The myeloma landscape in Australia and New Zealand: the first 8 years of the myeloma and related diseases registry (MRDR)","volume":"21","author":"Bergin","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.leukres.2024.107469_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.31128\/AJGP-01-18-4473","article-title":"Multiple myeloma: updated approach to management in 2018","volume":"47","author":"Tomlinson","year":"2018","journal-title":"Aust. J. Gen. Pract."},{"issue":"8","key":"10.1016\/j.leukres.2024.107469_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2024.107469_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2024.107469_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107469_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"4\u20135","key":"10.1016\/j.leukres.2024.107469_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updat."},{"issue":"11","key":"10.1016\/j.leukres.2024.107469_bib11","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2024.107469_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.leukres.2024.107469_bib13","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1128\/MCB.24.17.7469-7482.2004","article-title":"Activating transcription factor 4 is translationally regulated by hypoxic stress","volume":"24","author":"Blais","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"Pt 2","key":"10.1016\/j.leukres.2024.107469_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1042\/bj20020391","article-title":"Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response","volume":"366","author":"Okada","year":"2002","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.leukres.2024.107469_bib15","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2024.107469_bib16","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.leukres.2024.107469_bib17","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2a promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2024.107469_bib18","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3324\/haematol.2020.253526","article-title":"Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2024.107469_bib19","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1002\/jcp.26245","article-title":"The MIP-1alpha autocrine loop contributes to decreased sensitivity to anticancer drugs","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107469_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/bjh.13596","article-title":"Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma","volume":"171","author":"Mrozik","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"27","key":"10.1016\/j.leukres.2024.107469_bib21","doi-asserted-by":"crossref","first-page":"43602","DOI":"10.18632\/oncotarget.17115","article-title":"Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress","volume":"8","author":"Wallington-Beddoe","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.leukres.2024.107469_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1096\/fba.2020-00027","article-title":"Characterization of the role of Samsn1 loss in multiple myeloma development","volume":"2","author":"Friend","year":"2020","journal-title":"FASEB Bioadv."},{"issue":"4","key":"10.1016\/j.leukres.2024.107469_bib23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.leukres.2024.107469_bib24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2005-02-0516","article-title":"Development of functional human blood and immune systems in NOD\/SCID\/IL2 receptor {gamma} chain(null) mice","volume":"106","author":"Ishikawa","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107469_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B Cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2024.107469_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/0008-5472.CAN-08-3858","article-title":"Inhibition of eIF2\u03b1 dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy","volume":"69","author":"Schewe","year":"2009","journal-title":"Cancer Res."},{"issue":"5453","key":"10.1016\/j.leukres.2024.107469_bib28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.287.5453.664","article-title":"Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1","volume":"287","author":"Urano","year":"2000","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.leukres.2024.107469_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2024.107469_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","author":"Allmeroth","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.leu.2402717","article-title":"Expression and function of chemokine receptors in human multiple myeloma","volume":"17","author":"Moller","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","article-title":"Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM","volume":"120","author":"Uneda","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107469_bib34","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2024.107469_bib35","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","article-title":"Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cyto.2013.06.313","article-title":"CCR1\/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2\/9 and by activating ERK and Rac signaling","volume":"64","author":"Kato","year":"2013","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.leukres.2024.107469_bib37","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2024.107469_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00210-002-0588-0","article-title":"Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors","volume":"366","author":"Seifert","year":"2002","journal-title":"Arch. Pharmacol."},{"issue":"45","key":"10.1016\/j.leukres.2024.107469_bib39","doi-asserted-by":"crossref","first-page":"32194","DOI":"10.1074\/jbc.M113.503797","article-title":"The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, \u03b2-arrestin-mediated internalization","volume":"288","author":"Gilliland","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.leukres.2024.107469_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069668","article-title":"Modulation of the Akt pathway reveals a novel link with PERK\/eIF2\u03b1, which is relevant during hypoxia","volume":"8","author":"Blaustein","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib41","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1038\/s41598-017-16662-1","article-title":"AKT-mTOR signaling modulates the dynamics of IRE1 RNAse activity by regulating ER-mitochondria contacts","volume":"7","author":"Sanchez-Alvarez","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.leukres.2024.107469_bib42","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/0008-5472.CAN-13-3652","article-title":"Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition","volume":"74","author":"Mimura","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2024.107469_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0463.2011.02836.x","article-title":"Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt\/mTOR activity","volume":"120","author":"Que","year":"2012","journal-title":"APMIS"},{"issue":"10","key":"10.1016\/j.leukres.2024.107469_bib44","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2024.107469_bib45","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107469_bib46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2141.2010.08113.x","article-title":"The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome","volume":"149","author":"Vekemans","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107469_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.leukres.2024.107469_bib48","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2024.107469_bib49","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2016-03-706077","article-title":"MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma","volume":"128","author":"Qiang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107469_bib50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12885-018-4602-4","article-title":"MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma","volume":"18","author":"Qiang","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T19:06:41Z","timestamp":1720120001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":50,"alternative-id":["S0145212624000353"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107469","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107469"}}